[C:1]([O:5][C:6](=[O:32])[CH2:7][N:8](S(C1C=CC(OCC2C=CC=CC=2)=CC=1)(=O)=O)[CH2:9][CH2:10][CH2:11][C:12](=[O:14])[CH3:13])([CH3:4])([CH3:3])[CH3:2].CC(C)([O-])C.[K+].Cl>O1CCCC1.O>[C:1]([O:5][C:6]([CH:7]1[C:12]([OH:14])([CH3:13])[CH2:11][CH2:10][CH2:9][NH:8]1)=[O:32])([CH3:4])([CH3:3])[CH3:2]To a solution [(4-benzyloxy-benzenesulfonyl)-(4-oxo-pentyl)-amino]-acetic acid tert-butyl ester (compound of formula XVII, 25 g, 56 mmol) in 200 ml of tetrahydrofuran was added potassium tert-butoxide (24 ml of a 1M solution in tetrahydrofuran, 24 mmol). After stirring for about 24 hours at a temperature of about 20° C. to about 25° C., the mixture was diluted with water, acidified with 1M hydrochloric acid and extracted 3 times into ethyl acetate. The combined organic layers were dried over sodium sulfate, filtered and concentrated in vacuo. The stereoisomers were separated by preparative HPLC on a Chiralpak AD column® eluting with 2-propanol-hexane, affording approximately 4 g of each stereoisomer of 1-[4-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic acid tert-butyl ester (compound of formula XVIII) as a colorless oil.